Published in Cancer Res on June 08, 2010
Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One (2012) 2.06
The genetics of osteosarcoma. Sarcoma (2012) 1.33
The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma (2010) 1.18
The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol (2013) 1.11
NF-κB and cancer: a paradigm of Yin-Yang. Am J Cancer Res (2010) 1.08
WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci U S A (2014) 1.03
Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res (2012) 0.96
Common Chromosomal Fragile Site Gene WWOX in Metabolic Disorders and Tumors. Int J Biol Sci (2014) 0.95
Osteosarcomagenesis: modeling cancer initiation in the mouse. Sarcoma (2011) 0.94
Common fragile site tumor suppressor genes and corresponding mouse models of cancer. J Biomed Biotechnol (2010) 0.93
Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol (2013) 0.91
Conditional Wwox deletion in mouse mammary gland by means of two Cre recombinase approaches. PLoS One (2012) 0.89
Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One (2014) 0.88
Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med Genomics (2013) 0.88
Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma. Chin J Cancer (2014) 0.86
Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep (2015) 0.85
The tumor suppressor WW domain-containing oxidoreductase modulates cell metabolism. Exp Biol Med (Maywood) (2014) 0.85
WWOX: a fragile tumor suppressor. Exp Biol Med (Maywood) (2014) 0.84
Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab (2012) 0.83
Association of polymorphisms in WWOX gene with risk and outcome of osteosarcoma in a sample of the young Chinese population. Onco Targets Ther (2016) 0.83
Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders. Curr Osteoporos Rep (2014) 0.82
Alteration of WWOX in human cancer: a clinical view. Exp Biol Med (Maywood) (2015) 0.80
Regulation of cell signaling and apoptosis by tumor suppressor WWOX. Exp Biol Med (Maywood) (2015) 0.80
WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma. Cancer Res (2016) 0.79
WWOX modulates the ATR-mediated DNA damage checkpoint response. Oncotarget (2016) 0.79
Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer. Exp Biol Med (Maywood) (2014) 0.77
Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase. Exp Biol Med (Maywood) (2014) 0.77
Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet (2016) 0.75
WWOX inhibits the invasion of lung cancer cells by downregulating RUNX2. Cancer Gene Ther (2016) 0.75
The role of WWOX polymorphisms on COPD susceptibility and pulmonary function traits in Chinese: a case-control study and family-based analysis. Sci Rep (2016) 0.75
Decreased WWOX expression promotes angiogenesis in osteosarcoma. Oncotarget (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol (2002) 10.03
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 5.56
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol (2005) 5.55
A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J (1999) 4.66
WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res (2000) 4.07
Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev (2006) 2.85
Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr (2004) 2.81
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev (2008) 2.74
Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet (2000) 2.56
Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37
Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol (2006) 2.27
The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol (2005) 2.18
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol (2004) 1.88
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene (2009) 1.87
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene. J Cell Physiol (2000) 1.76
The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem (2008) 1.67
WWOX in biological control and tumorigenesis. J Cell Physiol (2007) 1.66
Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol (2006) 1.57
WWOX: its genomics, partners, and functions. J Cell Biochem (2009) 1.52
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
Common fragile sites. Cancer Lett (2005) 1.48
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer (2009) 1.35
Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet (2009) 1.33
WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol (2010) 1.16
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res (2008) 1.16
Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer (2005) 1.10
Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep (2008) 1.09
Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res (2008) 1.08
Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori (2009) 1.02
Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer (2005) 0.99
Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions. Int J Biochem Cell Biol (2006) 0.86
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol (2005) 5.55
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
The sirtuin SIRT6 regulates lifespan in male mice. Nature (2012) 4.07
Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem (2005) 3.97
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem (2009) 3.62
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Biology and therapeutic advances for pediatric osteosarcoma. Oncologist (2004) 3.34
Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase. J Cell Physiol (2006) 3.32
A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci U S A (2008) 3.29
Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord (2006) 3.25
MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19
The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol (2004) 3.09
MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res (2008) 2.97
Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr (2004) 2.81
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Primary mouse embryonic fibroblasts: a model of mesenchymal cartilage formation. J Cell Physiol (2004) 2.59
miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res (2012) 2.52
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37
Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol (2002) 2.35
Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res (2010) 2.30
A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci U S A (2010) 2.29
Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature (2007) 2.28
Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol (2006) 2.27
CCAAT/enhancer-binding proteins (C/EBP) beta and delta activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. J Biol Chem (2001) 2.27
Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene (2004) 2.25
Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res (2003) 2.20
The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol (2005) 2.18
BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network. J Biol Chem (2006) 2.15
Relation between cord blood mercury levels and early child development in a World Trade Center cohort. Environ Health Perspect (2008) 2.13
Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J (2004) 2.12
A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc Natl Acad Sci U S A (2011) 2.05
MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol (2012) 2.05
The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci U S A (2006) 2.01
Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell (2012) 1.99
Dlx3 transcriptional regulation of osteoblast differentiation: temporal recruitment of Msx2, Dlx3, and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene. Mol Cell Biol (2004) 1.99
Human hepatic stem cell and maturational liver lineage biology. Hepatology (2011) 1.99
Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem (2001) 1.99
Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology (2006) 1.98
Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology (2011) 1.94
Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining. Proc Natl Acad Sci U S A (2010) 1.94
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A (2010) 1.94
Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet (2003) 1.94
The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem (2005) 1.93
Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc Natl Acad Sci U S A (2007) 1.91